ExeVir, which is developing single domain antibody therapies providing broad protection against viral infections, and Mithra Pharmaceuticals have formed a new collaboration to utilize the fill and finish capabilities for ExeVir’s therapies at Mithra’s integrated R&D and manufacturing platform, Mithra CDMO.   Following the final close of its $50 million Series A financing earlier this year, ExeVir is accelerating the development of XVR011 for the potential treatment and prevention...